• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

Recent Advances in the Study of (1-ethyl-3-methyl-pyrazol-4-yl)methanamine Dihydrochloride (CAS: 1609407-55-7)

The compound (1-ethyl-3-methyl-pyrazol-4-yl)methanamine dihydrochloride (CAS: 1609407-55-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This small molecule, characterized by its pyrazole core and amine functionality, has shown promising potential in various therapeutic applications, particularly in the modulation of protein-protein interactions and enzyme inhibition. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, aiming to elucidate its mechanism of action and therapeutic efficacy.

One of the key findings in recent literature is the role of (1-ethyl-3-methyl-pyrazol-4-yl)methanamine dihydrochloride as a selective inhibitor of certain kinases involved in inflammatory and oncogenic pathways. Researchers have demonstrated its ability to bind with high affinity to specific kinase domains, thereby disrupting downstream signaling cascades. This property makes it a valuable candidate for the development of targeted therapies for diseases such as cancer and autoimmune disorders. Structural-activity relationship (SAR) studies have further refined the compound's scaffold to enhance its potency and selectivity.

In addition to its kinase inhibitory activity, (1-ethyl-3-methyl-pyrazol-4-yl)methanamine dihydrochloride has been investigated for its potential as a building block in the synthesis of more complex pharmacophores. Its amine group serves as a versatile handle for further chemical modifications, enabling the creation of derivatives with improved pharmacokinetic properties. Recent synthetic methodologies have focused on optimizing the yield and purity of this compound, ensuring its suitability for large-scale production and preclinical testing.

Another area of interest is the compound's application in drug discovery pipelines. High-throughput screening (HTS) campaigns have identified (1-ethyl-3-methyl-pyrazol-4-yl)methanamine dihydrochloride as a hit molecule for several targets, including G protein-coupled receptors (GPCRs) and ion channels. These findings have spurred further investigations into its therapeutic potential, with some studies reporting promising in vitro and in vivo results. For instance, animal models of neuropathic pain have shown significant alleviation of symptoms upon administration of this compound, suggesting its utility in pain management.

Despite these advancements, challenges remain in the development of (1-ethyl-3-methyl-pyrazol-4-yl)methanamine dihydrochloride as a therapeutic agent. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed through rigorous preclinical studies. Recent efforts have focused on formulating the compound in various delivery systems, including nanoparticles and liposomes, to enhance its therapeutic index. Additionally, computational modeling and molecular dynamics simulations are being employed to predict its behavior in biological systems and guide further optimization.

In conclusion, (1-ethyl-3-methyl-pyrazol-4-yl)methanamine dihydrochloride (CAS: 1609407-55-7) represents a promising scaffold in chemical biology and drug discovery. Its diverse biological activities and synthetic versatility make it a valuable tool for researchers aiming to develop novel therapeutics. Future studies should focus on translating these findings into clinical applications, addressing the aforementioned challenges, and exploring its potential in combination therapies. The ongoing research underscores the importance of this compound in advancing our understanding of disease mechanisms and therapeutic interventions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)